Probenecid

Starting urate lowering therapy during a gout flare does not impact the flare’s severity, duration or risk for recurrence over the following month, according to a systematic review and meta-analysis.

A more intensive serum urate target is difficult to achieve with oral urate-lowering therapy, compared with a standard target of 0.3 mmol/L, and fails to improve bone erosion scores in patients with erosive gout, according to a study.

A new study suggests that the gout drug probenecid could potentially be used to prevent or treat COVID-19 as well as other respiratory diseases. It was the top story in rheumatology last week.

Probenecid could potentially be used to prevent or treat not only COVID-19, but other respiratory illnesses including influenza and respiratory syncytial virus infection, according to data published in Scientific Reports.